| Autor: |
Ahou-Alfa, Ghassan K., Johnson, Philip, Knox, Jennifer J., Capanu, Marinela, Davidenko, Irina, Lacava, Juan, Leung, Thomas, Gansukh, Bolorsukh, Saltz, Leonard B. |
| Předmět: |
|
| Zdroj: |
JAMA: Journal of the American Medical Association; 11/17/2010, Vol. 304 Issue 19, p2154-2160, 7p, 1 Diagram, 2 Charts, 2 Graphs |
| Abstrakt: |
The article focuses on randomized phase 3 trial which evaluated the efficacy and safety of doxorubicin plus sorafenib compared with doxorubicin alone in patients with advanced hepatocellular carcinoma (HCC). Patients with median age of 65 years and with advanced HCC were randomly assigned to receive doxorubicin intravenously every 21 days plus either sorafenib or placebo rally two times a day. Results indicated that treatment with sorafenib plus doxorubicin compared with doxorubicin monotherapy resulted in greater media time to progression, overall survival and progression-free survival. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
